Naoto T Ueno, MD, PhD@teamoncology
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. DESTINY-03 breast cancer data is now published in @NEJM. An important milestone and practice-changing. https://www.nejm.org/doi/full/10.1056/NEJMoa2115022#.YkSCPR1OZEg.twitter… #bcsm #oncoalert
posted at 01:18:03